Identification of proteins expressed differently among surgically resected stage I lung adenocarcinomas

Clinical Biochemistry

Volumn 46, Issue 4-5, 2013, Pages 369-377

  Ha, Eun Sil ^a   Choi, Seonyoung ^a   In, Kwang Ho ^a   Lee, Seung Hyeun ^a   Lee, Eun Joo ^a   Lee, Sang Yeub ^a   Kim, Je Hyeong ^a   Shin, Chol ^a   Shim, Jae Jeong ^a   Kang, Kyung Ho ^a   Phark, Sohee ^a   Sul, Donggeun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Biomarker; Lung adenocarcinoma; Prognosis; Proteomic analysis

Indexed keywords

LIPOCORTIN 1; SERINE PROTEINASE INHIBITOR; TAU TUBULIN KINASE 2; THYMIDINE PHOSPHORYLASE; TUBULIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER TISSUE; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; DOWN REGULATION; ELECTROSPRAY MASS SPECTROMETRY; FEMALE; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; GENE EXPRESSION; HUMANS; ISOELECTRIC FOCUSING; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROTEOME; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 84873705551     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.11.014     Document Type: Article

References (45)

1. World Health Organization The GlobalBurden of Disease: 2004 Update 2008, World Health Organization, Geneva.
2. Martini N., Bains M.S., Burt M.E., Zakowski M.F., McCormack P., Rusch V.W., et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer. J Thorac Cardiovasc Surg 1995, 109:120-129.
3. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 2002, 21:6970-6981.
4. Tomizawa Y., Nakajima T., Kohno T., Saito R., Yamaguchi N., Yokota J., et al. Clinicopathological significance of Fhit protein expression in stage I non-small cell lung carcinoma. Cancer Res 1998, 58:5478-5483.
5. Khuri F.R., Lotan R., Kemp B.L., Lippman S.M., Wu H., Feng L., et al. Retinoic acid receptor-beta as a prognostic indicator in stage I non-small-cell lung cancer. J Clin Oncol 2000, 18:2798-2804.
6. Brock M.V., Hooker C.M., Ota-Machida E., Han Y., Guo M., Ames S., et al. DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008, 358:1118-1128.
7. Alaiya A.A., Franzen B., Auer G., Linder S. Cancer proteomics: from identification of novel markers to creation of artifical learning models for tumor classification. Electrophoresis 2000, 21:1210-1217.
8. Bhattacharjee A., Richards W.G., Staunton J., Li C., Monti S., Vasa P., et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A 2001, 98:13790-13795.
9. Beer D.G., Kardia S.L., Huang C.C., Giordano T.J., Levin A.M., Misek D.E., et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002, 8:816-824.
10. Wilkins M.R., Sanchez J.C., Williams K.L., Hochstrasser D.F. Current challenges and future applications for protein maps and post-translational vector maps in proteome projects. Electrophoresis 1996, 17:830-838.
11. Solassol J., Jacot W., Lhermitte L., Boulle N., Maudelonde T., Mangé A., et al. Clinical proteomics and mass spectrometry profiling for cancer detection. Expert Rev Proteomics 2006, 3:311-320.
12. Yanagisawa K., Tomida S., Shimada Y., Yatabe Y., Mitsudomi T., Takahashi T. A 25-signal proteomic signature and outcome for patients with resected non-small-cell lung cancer. J Natl Cancer Inst 2007, 99:858-867.
13. Gharib T.G., Chen G., Wang H., Huang C.C., Prescott M.S., Shedden K., et al. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 2002, 4:440-448.
14. Maeda J., Hirano T., Ogiwara A., Akimoto S., Kawakami T., Fukui Y., et al. Proteomic analysis of stage I primary lung adenocarcinoma aimed at individualisation of postoperative therapy. Br J Cancer 2008, 98:596-603.
15. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
16. Beckman G., Eklund A., Frohlander N., Stjernberg N. Haptoglobin groups and lung cancer. Hum Hered 1986, 36:258-260.
17. Awadallah S.M., Atoum M.F. Haptoglobin polymorphism in breast cancer patients form Jordan. Clin Chim Acta 2004, 341:17-21.
18. Zhao C., Annamalai L., Guo C., Kothandaraman N., Koh S.C., Zhang H., et al. Circulating haptoglobin is an independent prognostic factor in the sera of patients with epithelial ovarian cancer. Neoplasia 2007, 9:1-7.
19. Hanger D.P., Betts J.C., Loviny T.L., Blackstock W.P., Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry. J Neurochem 1998, 71:2465-2476.
20. Pauly J.L., Schuller M.G., Zelcer A.A., Kirss T.A., Gore S.S., Germain M.J. Identification and comparative analysis of thymidine phosphorylase in the plasma of healthy subjects and cancer patients. J Natl Cancer Inst 1977, 58:1587-1590.
21. Sato J., Sata M., Nakamura H., Inoue S., Wada T., Takabatake N., et al. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer 2003, 106:863-870.
22. Yamashita J., Ogawa M., Abe M., Nishida M. Platelet-derived endothelial cell growth factor/thymidine phosphorylase concentrations differ in small cell and non-small cell lung cancer. Chest 1999, 116:206-211.
23. Raynal P., Pollard H.B. Annexins: the problem of assessing the biological role for a gene family of multifunctional calcium- and phospholipid-binding proteins. Biochim Biophys Acta 1994, 1197:63-93.
24. Ahn S.H., Sawada H., Ro J.Y., Nicolson G.L. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin Exp Metastasis 1997, 15:151-156.
25. Masaki T., Tokuda M., Watanabe S., Fujimura T., Miyamoto K., Ohnishi M., et al. Enhanced expression of the protein kinase substrate annexin in human hepatocellular carcinoma. Hepatology 1996, 24:72-81.
26. Bai X.F., Ni X.G., Zhao P., Liu S.M., Wang H.X., Guo B., et al. Overexpression of annexin 1 in pancreatic cancer and its clinical significance. World J Gastroenterol 2004, 10:1466-1470.
27. Pencil S.D., Toth M. Elevated levels of annexin I protein in vitro and in vivo in rat and human mammary adenocarcinoma. Clin Exp Metastasis 1998, 16:113-121.
28. Paweletz C.P., Ornstein D.K., Roth M.J., Bichsel V.E., Gillespie J.W., Calvert V.S., et al. Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res 2000, 60:6293-6297.
29. De B.K., Misono K.S., Lukas T.J., Mroczkowski B., Cohen S. A calcium-dependent 35-kilodalton substrate for epidermal growth factor receptor/kinase isolated from normal tissue. J Biol Chem 1986, 261:13784-13792.
30. Rhee H.J., Kim G.Y., Huh J.W., Kim S.W., Na D.S. Annexin I is a stress protein induced by heat, oxidative stress and a sulfhydryl-reactive agent. Eur J Biochem 2000, 267:3220-3225.
31. Lu K.P., Hanes S.D., Hunter T. A human peptidyl-prolyl isomerase essential for regulation of mitosis. Nature 1996, 380:544-547.
32. He J., Zhou F., Shao K., Hang J., Wang H., Rayburn E., et al. Overexpression of Pin1 in non-small cell lung cancer (NSCLC) and its correlation with lymph node metastases. Lung Cancer 2007, 56:51-58.
33. Silacci P., Mazzolai L., Gauci C., Stergiopulos N., Yin H.L., Hayoz D. Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 2004, 61:2614-2623.
34. Nomura H., Uzawa K., Ishigami T., Kouzu Y., Koike H., Ogawara K., et al. Clinical significance of gelsolin-like actin-capping protein expression in oral carcinogenesis: an immunohistochemical study of premalignant and malignant lesions of the oral cavity. BMC Cancer 2008, 8:39.
35. Thompson C.C., Ashcroft F.J., Patel S., Saraga G., Vimalachandram D., Prime W., et al. Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut 2007, 56:95-106.
36. Partheen K., Levan K., Osterberg L., Claesson I., Fallenius G., Sundfeldt K., et al. Four potential biomarkers as prognostic factors in stage III serous ovarian adenocarcinomas. Int J Cancer 2008, 123:2130-2137.
37. Watari A., Takaki K., Higashiyama S., Li Y., Satomi Y., Takao T., et al. Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 2006, 25:7373-7380.
38. Wadhwa R., Kaul S.C., Komatsu Y., Ikawa Y., Sarai A., Sugimoto Y. Identification and differential expression of yeast SEC23-related gene (Msec23) in mouse tissues. FEBS Lett 1993, 315:193-196.
39. Silverman G.A., Bird P.I., Carrell R.W., Church F.C., Coughlin P.B., Gettins P.G., et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions, and a revised nomenclature. J Biol Chem 2001, 276:33293-33296.
40. Krasnov G.S., Oparina N., Khankin S.L., Mashkova T.D., Ershov A.N., Zatsepina O.G., et al. Colorectal cancer 2D-proteomics: identification of altered protein expression. Mol Biol (Mosk) 2009, 43:348-356.
41. Shi Y.Y., Wang H.C., Yin Y.H., Sun W.S., Li Y., Zhang C.Q., et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 2005, 92:929-934.
42. Mikuriya K., Kuramitsu Y., Ryozawa S., Fujimoto M., Mori S., Oka M., et al. Expression of glycolytic enzymes is increased in pancreatic cancerous tissues as evidenced by proteomic profiling by two-dimensional electrophoresis and liquid chromatography-mass spectrometry/mass spectrometry. Int J Oncol 2007, 30:849-855.
43. Huang Q., Chen W., Wang L., Wang L., Lin W., Lin J., et al. Identification of transgelin as a potential novel biomarker for gastric adenocarcinoma based on proteomics technology. J Cancer Res Clin Oncol 2008, 134:1219-1227.
44. Shields J.M., Rogers-Graham K., Der C.J. Loss of transgelin in breast and colon tumors and in RIE-1 cells by Ras deregulation of gene expression through Raf-independent pathways. J Biol Chem 2002, 277:9790-9799.
45. Yang Z., Chang Y.J., Miyamoto H., Ni J., Niu Y., Chen Z., et al. Transgelin functions as a suppressor via inhibition of ARA54-enhanced androgen receptor transactivation and prostate cancer cell growth. Mol Endocrinol 2007, 21:343-358.